Investment Stage

Focus Areas

About Investor

Amy Kruse, PhD, is a venture partner at Prime Movers Lab, where she serves on the boards of portfolio companies including Paradromics, Gilgamesh Pharmaceuticals, Cognixion, Dimension Bio, and Attune Neurosciences. Prime Movers Lab describes itself as an early-stage investor in breakthrough scientific startups. Before joining the firm, Kruse was chief scientific officer at Optios and VP and CTO at Cubic Global Defense. Earlier in her career, she was a civilian program manager at DARPA, where she created and oversaw the agency’s first performance-oriented neuroscience programs.